Metsera, Inc. (MTSR) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en New York City, NY, United States. El CEO actual es Christopher Whitten Bernard.
MTSR tiene fecha de IPO 2025-01-31, 93 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $7.43B.
Metsera, Inc. is a clinical-stage biotechnology company developing injectable and oral hormone analog peptides designed to treat obesity, overweight, and related metabolic disorders. The company's pipeline includes MET-097i and MET-233i for obesity and overweight management, as well as MET-002, MET-224o, MET-067i, and MET-034i for treating conditions including diabetes and obesity. Founded in 2022 and based in New York, Metsera is advancing nutrient-stimulated therapeutic candidates toward clinical development.
